Neurodegenerative Disease Management
Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4
Trial in peopleInterventions
Papers by Niraj Patel
2 results
- AAIC 2025 Abstract
Characteristics and staging of patients with Alzheimer's disease: real‐world data from the United Kingdom
Study in peoplePopulations